OK Biotech Co (4155) Fair Value & Analysis
Healthcare · TW · Market cap 2.2B TWD
Fair value as of: Jul 21, 2026
From 16 valuation models · updated 20 days ago
Share price −6.1% over the past month.
Below-average quality, and screening another 42% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (10.66 TWD). The favourable scenario is already priced in.
- Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 12.90 TWD – 37.31 TWD · fair‑value band 6.40 TWD – 10.66 TWD · the 14.65 TWD price screens above the 8.53 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
OK Biotech Co (4155) currently trades at 14.65 TWD, while our model-based Fair Value estimate is 8.53 TWD, implying the stock looks roughly 41.8% overvalued today. The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, OK Biotech Co generated revenue of 1.5B TWD at a net margin of 7.4%. Revenue declined 6.9% year over year. It earns a return on equity of 5.2%. Net debt stands at 720M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 6.40 TWD (bear case) to 10.66 TWD (bull case); at 14.65 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 15% below its 52-week high and 14% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -42%, 4155 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Asset-Based (12.05 TWD) versus Dividend Discount (4.74 TWD). Highest evidence: Residual Income (76).
Notify me when 4155 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 38 · Market factors (momentum, volatility) 54
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
OK Biotech Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of blood glucose monitoring systems and homecare healthcare devices in Taiwan, the rest of Asia, America, Africa, and Europe. The company offers nebulizers, blood glucose meters, glucometers, blood sugar meters, and blood glucose test strips.
Full company description
OK Biotech Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of blood glucose monitoring systems and homecare healthcare devices in Taiwan, the rest of Asia, America, Africa, and Europe. The company offers nebulizers, blood glucose meters, glucometers, blood sugar meters, and blood glucose test strips. It also provides OTC hearing aids, multi-frequency therapy devices, and factory setup solutions, as well as professional OEM/ODM customized services. The company sells its products under the OKB and Prodigy brands. OK Biotech Co., Ltd. was incorporated in 2004 and is headquartered in Hsinchu City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
OK Biotech Co reported revenue of 1.6B TWD in FY2025 versus 1.3B TWD in FY2021, a compound +5.4%/yr. Reported net income was 82.4M TWD in FY2025, compounding +27.3%/yr from FY2021.
of which total revenue +7.1 pp · buybacks/dilution −9.2 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
4155 screens 42% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare OK Biotech Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is OK Biotech Co (4155) overvalued or undervalued?
What is the fair value of 4155?
What is the quality score of 4155?
What is the revenue of OK Biotech Co (4155)?
What is the net profit margin of 4155?
Does OK Biotech Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track OK Biotech Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.